Apollomics (APLM) Competitors

$14.21 +0.12 (+0.87%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$14.92 +0.70 (+4.95%)

As of 05/22/2026 06:21 PM Eastern

APLM vs. EDSA, ACOG, THAR, TTRX, and AIFC

Should you buy Apollomics stock or one of its competitors? MarketBeat compares Apollomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apollomics include Edesa Biotech (EDSA), Alpha Cognition (ACOG), Tharimmune (THAR), Turn Therapeutics (TTRX), and ALT5 Sigma (AIFC). These companies are all part of the "pharmaceutical products" industry.

How does Apollomics compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Edesa Biotech had 6 more articles in the media than Apollomics. MarketBeat recorded 6 mentions for Edesa Biotech and 0 mentions for Apollomics. Edesa Biotech's average media sentiment score of 0.08 beat Apollomics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Edesa Biotech	Neutral
Apollomics	Neutral

Apollomics' return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
Apollomics	N/A	N/A	N/A

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Edesa Biotech has higher earnings, but lower revenue than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Apollomics	$8.50M	3.68	-$10.94M	N/A	N/A

Edesa Biotech has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

Edesa Biotech presently has a consensus price target of $5.00, suggesting a potential downside of 52.20%. Given Edesa Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Edesa Biotech is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Edesa Biotech beats Apollomics on 7 of the 12 factors compared between the two stocks.

How does Apollomics compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Apollomics has lower revenue, but higher earnings than Alpha Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	12.46	-$20.67M	-$1.35	N/A
Apollomics	$8.50M	3.68	-$10.94M	N/A	N/A

Alpha Cognition has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

19.1% of Apollomics shares are owned by institutional investors. 14.0% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Alpha Cognition had 6 more articles in the media than Apollomics. MarketBeat recorded 6 mentions for Alpha Cognition and 0 mentions for Apollomics. Alpha Cognition's average media sentiment score of 0.56 beat Apollomics' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Cognition	Positive
Apollomics	Neutral

Alpha Cognition presently has a consensus target price of $16.00, suggesting a potential upside of 173.50%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alpha Cognition is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Apollomics' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Apollomics	N/A	N/A	N/A

Summary

Alpha Cognition beats Apollomics on 9 of the 14 factors compared between the two stocks.

How does Apollomics compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Tharimmune's average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company	Overall Sentiment
Tharimmune	Neutral
Apollomics	Neutral

Apollomics' return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Apollomics	N/A	N/A	N/A

Tharimmune has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Apollomics has higher revenue and earnings than Tharimmune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Apollomics	$8.50M	3.68	-$10.94M	N/A	N/A

Summary

Apollomics beats Tharimmune on 6 of the 7 factors compared between the two stocks.

How does Apollomics compare to Turn Therapeutics?

Apollomics (NASDAQ:APLM) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Turn Therapeutics had 2 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Apollomics. Turn Therapeutics' average media sentiment score of 0.19 beat Apollomics' score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Neutral
Turn Therapeutics	Neutral

Turn Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 55.95%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Turn Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Turn Therapeutics	N/A	N/A	N/A

19.1% of Apollomics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Turn Therapeutics has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.68	-$10.94M	N/A	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

Summary

Turn Therapeutics beats Apollomics on 6 of the 8 factors compared between the two stocks.

How does Apollomics compare to ALT5 Sigma?

Apollomics (NASDAQ:APLM) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, Apollomics' average media sentiment score of 0.00 beat ALT5 Sigma's score of -0.47 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Neutral
ALT5 Sigma	Neutral

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.68	-$10.94M	N/A	N/A
ALT5 Sigma	$24.84M	5.03	-$344.51M	N/A	N/A

Apollomics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Apollomics' return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Apollomics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

Summary

Apollomics beats ALT5 Sigma on 6 of the 10 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLM vs. The Competition

Export

Metric	Apollomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.93M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	N/A	18.74	21.22	25.66
Price / Sales	3.68	323.98	562.28	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-4.92	7.09	10.31	7.14
Net Income	-$10.94M	$24.45M	$3.57B	$335.98M
7 Day Performance	-1.00%	6.38%	6.43%	4.15%
1 Month Performance	6.26%	2.43%	3.57%	2.54%
1 Year Performance	100.73%	62.98%	34.07%	35.06%

Apollomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLM Apollomics	0.8542 of 5 stars	$14.21 +0.9%	N/A	+100.7%	$30.93M	$8.50M	N/A	45
EDSA Edesa Biotech	1.6895 of 5 stars	$14.01 +5.6%	$5.00 -64.3%	+433.7%	$123.44M	N/A	N/A	20	Gap Up
ACOG Alpha Cognition	4.2541 of 5 stars	$5.63 -5.5%	$16.00 +184.4%	-36.0%	$122.44M	$10.22M	N/A	N/A	Gap Down
THAR Tharimmune	N/A	$3.19 +5.6%	N/A	+159.3%	$120.36M	N/A	N/A	2
TTRX Turn Therapeutics	3.0035 of 5 stars	$3.88 -2.5%	$8.00 +106.2%	N/A	$115.59M	N/A	N/A	2	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLM) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apollomics (APLM) Competitors

APLM vs. EDSA, ACOG, THAR, TTRX, and AIFC

How does Apollomics compare to Edesa Biotech?

Summary

How does Apollomics compare to Alpha Cognition?

Summary

How does Apollomics compare to Tharimmune?

Summary

How does Apollomics compare to Turn Therapeutics?

Summary

How does Apollomics compare to ALT5 Sigma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apollomics (APLM) Competitors

APLM vs. EDSA, ACOG, THAR, TTRX, and AIFC

How does Apollomics compare to Edesa Biotech?

Does the media favor EDSA or APLM?

Is EDSA or APLM more profitable?

Do institutionals and insiders have more ownership in EDSA or APLM?

Which has better valuation & earnings, EDSA or APLM?

Which has more volatility and risk, EDSA or APLM?

Do analysts prefer EDSA or APLM?

Summary

How does Apollomics compare to Alpha Cognition?

Which has stronger valuation and earnings, ACOG or APLM?

Which has more risk & volatility, ACOG or APLM?

Do insiders and institutionals hold more shares of ACOG or APLM?

Does the media prefer ACOG or APLM?

Do analysts rate ACOG or APLM?

Is ACOG or APLM more profitable?

Summary

How does Apollomics compare to Tharimmune?

Do analysts rate THAR or APLM?

Does the media prefer THAR or APLM?

Is THAR or APLM more profitable?

Which has more volatility & risk, THAR or APLM?

Do institutionals & insiders hold more shares of THAR or APLM?

Which has better earnings & valuation, THAR or APLM?

Summary

How does Apollomics compare to Turn Therapeutics?

Does the media refer more to APLM or TTRX?

Do analysts rate APLM or TTRX?

Is APLM or TTRX more profitable?

Do institutionals and insiders have more ownership in APLM or TTRX?

Which has stronger valuation & earnings, APLM or TTRX?

Summary

How does Apollomics compare to ALT5 Sigma?

Does the media favor APLM or AIFC?

Do institutionals and insiders have more ownership in APLM or AIFC?

Do analysts prefer APLM or AIFC?

Which has higher valuation & earnings, APLM or AIFC?

Is APLM or AIFC more profitable?

Which has more risk & volatility, APLM or AIFC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools